- Adherence among chronic disease patients can lead to big savings
- Pfizer forms licensing agreement with Seattle Genetics
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Walgreens launches high-impact push in support of World AIDS Day campaign
- Medication adherence could be blockbuster for specialty
PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic epilepsy drug made by Wockhardt, the company said.
Wockhardt, based in India, announced the approval of lamotrigine extended-release tablets in the 25-mg, 50-mg, 100-mg, 200-mg and 300-mg strengths.
The drug is a generic version of GlaxoSmithKline's Lamictal XR. The U.S. market for the drug is about $250 million, according to IMS Health.